C4 Therapeutics (CCCC) Share-based Compensation (2019 - 2026)

C4 Therapeutics has reported Share-based Compensation for 8 years, with the latest figure at $2.7 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 51.5% year-over-year to $2.7 million; the trailing twelve-month figure through Mar 2026 stood at $16.3 million (down 43.83% YoY), and the FY2025 full-year result was $19.1 million, down 35.61% from the prior year.
• Share-based Compensation for Q1 2026 stood at $2.7 million, down from $4.0 million in the prior quarter.
• The five-year high for Share-based Compensation was $8.9 million in Q1 2022, with the low at $2.7 million in Q1 2026.
• Average Share-based Compensation over 5 years is $6.4 million, with a median of $6.4 million recorded in 2023.
• Year-over-year, Share-based Compensation soared 132.46% in 2022 and sank 51.5% in 2026.
• Tracing CCCC's Share-based Compensation over 5 years: stood at $6.9 million in 2022, then dropped by 8.09% to $6.4 million in 2023, then gained by 29.5% to $8.2 million in 2024, then slumped by 51.34% to $4.0 million in 2025, then plunged by 33.34% to $2.7 million in 2026.
• The last three Share-based Compensation figures came in at $2.7 million (Q1 2026), $4.0 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.

Peer Comparison